台灣食藥署(TFDA)已核准先驅生技提交的GF-CART01臨床試驗申請(IND)，該療法為針對血液型B細胞惡性腫瘤的CD20/CD19雙標靶CAR-T細胞治療！2025-02-11Our COO/CSO, Karen Wen was invited at Taiwan HSCT & Cell Therapy Congress 2024 in NTUH, Taiwan (July 13, 2024)2024-07-16 Our Founder/CEO/CSO, Sareina Wu, and our Director of Scientific communication, Marcus J. Calkins, will present our work as invited expert speakers at the 9th Annual CAR-TCR Summit in Boston, US. (September 17-20, 2024) For more information: https://car-tcr-summit.com/ Share0
